Evidence map›Paper›PMID 42168167›Full record

ArticleNature communications2026

Insulin receptor

Brandon T Hubbard, Yumin Ma, Rafael C Gaspar, Traci E LaMoia, Dongyan Zhang, Mario Kahn, Sylvie Dufour, Ali Nasiri, Gerald I Shulman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Brandon T HubbardDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-1957-4752
Yumin MaDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Rafael C GasparDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Traci E LaMoiaDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Dongyan ZhangDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Mario KahnDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Sylvie DufourDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Ali NasiriDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Gerald I ShulmanDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. gerald.shulman@yale.edu.ORCID http://orcid.org/0000-0003-1529-5668

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 1993 to 2026
$44.0M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI WAJAHAT Zafar MEHAL · 1986 to 2026
$31.1M
Medical Scientist Training ProgramT32GM136651 · NIGMS · YALE UNIVERSITY · PI BARBARA I KAZMIERCZAK · 2020 to 2026
$16.5M
In vivo Pathway Discovery in Autosomal Dominant Polycystic Kidney DiseaseRC2DK120534 · NIDDK · YALE UNIVERSITY · PI CAPLAN, MICHAEL J., SHULMAN, GERALD I · 2019 to 2023
$6.6M
INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32GM007324 · NIGMS · YALE UNIVERSITY · PI BENNETT, ANTON M · 1987 to 2022
$6.2M
Yale Center for Metabolic Phenotyping in Live Models of Obesity and DiabetesU2CDK134901 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 2023 to 2026
$3.8M
Effects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin ResistanceR01DK113984 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2017 to 2021
$3.7M
Development of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human PrimatesR01DK119968 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2019 to 2024
$2.7M
Mechanism of Renal Cortical Insulin ResistanceR01DK133143 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2022 to 2025
$2.3M
Elucidating the pathophysiology and molecular mechanisms of renal insulin resistanceF30DK131846 · NIDDK · YALE UNIVERSITY · PI HUBBARD, BRANDON · 2022 to 2025
$173k
The Mitochondrial Calcium Uniporter: Implications for NAFLD and Hepatic Insulin ResistanceF31DK126362 · NIDDK · YALE UNIVERSITY · PI LAMOIA, TRACI ELLEN · 2021 to 2023
$140k
NIDDK NIH HHS F30 DK131846NIDDK NIH HHS F31 DK126362NIDDK NIH HHS P30 DK034989NIDDK NIH HHS P30 DK045735NIDDK NIH HHS R01 DK113984NIDDK NIH HHS R01 DK119968NIDDK NIH HHS R01 DK133143NIDDK NIH HHS RC2 DK120534NIDDK NIH HHS U2C DK134901NIGMS NIH HHS T32 GM007324NIGMS NIH HHS T32 GM136651Novo Nordisk Fonden (Novo Nordisk Foundation) NNF25SA0106990U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) F30DK131846U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) F31DK12632U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) P30DK034989U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) P30DK134901U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK133143U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) RC2DK120534U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) U2CDK134901U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM136651
6 · The paper itself

Abstract

Impaired suppression of endogenous glucose production (EGP) drives end-organ damage in insulin resistance and type 2 diabetes. Although the liver is traditionally thought to mediate dysregulated EGP, the role of the renal cortex is less understood. Here, we investigate if high-fat diet (HFD) induces renal cortical insulin resistance while assessing renal glucose production (RGP) and mitochondrial metabolism in male mice. HFD increases plasma membrane sn-1,2-DAGs, PKCε translocation, and Insulin Receptor Kinase (IRK)

Indexed as

GluconeogenesisGlycerolInsulin ResistanceKidney CortexReceptor, InsulinAnimalsDiet, High-FatGlucoseInsulinMaleMiceMice, Inbred C57BLMitochondriaPhosphorylationProtein Kinase C-epsilonSignal TransductionGlucoseGlycerolInsulinProtein Kinase C-epsilonReceptor, Insulin

Identifiers

PMID42168167
PMCPMC13385832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.